Market Overview

UPDATE: Compass Point Upgrades DR Horton to Neutral on Updated Forecasts

Share:
Related DHI
4 Stock Charts That Oppenheimer Likes
CNBC's Stock Pops & Drops From March 24
Why Investors Should Consider Selling D. R. Horton At Its 52-Week High (Seeking Alpha)

Compass Point raised its rating on DR Horton (NYSE: DHI) from Sell to Neutral and raised its price target to $18.50.

Compass Point commented, "After a full model update we are raising estimates and, coupled with the stock's relative underperformance in the post-QE3 trade, we now feel DHI should perform in line with the rest of the space. Our price target increase reflects our increased 2013 EPS estimate to $0.93 from $0.87 as well as a consistent 5% assumed ROI. We still see downside in the shares to $18 but the stock is off 12% since the Fed announced QE3 in early September and has been the second worst performer in the homebuilding sector over that time frame."

DR Horton closed at $19.58 on Wednesday.

Latest Ratings for DHI

DateFirmActionFromTo
Mar 2015JMP SecuritiesUpgradesMarket PerformMarket Outperform
Mar 2015Keefe Bruyette & WoodsMaintainsMarket Perform
Jan 2015CitigroupDowngradesBuyNeutral

View More Analyst Ratings for DHI
View the Latest Analyst Ratings

Posted-In: Compass PointAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (DHI)

Around the Web, We're Loving...